Reoto Takei
Reoto Takei publishes mostly in Pulmonary and Respiratory Medicine, Epidemiology and Pathology and Forensic Medicine, on topics such as Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, Systemic Sclerosis and Related Diseases and Inflammatory Myopathies and Dermatomyositis.
- World rank
- #832,631 of 7,710,434 ranked researchers
- Rank in Japan
- #10,417 of 383,136
- Works
- 75
- Citations
- 977
- Citations per work
- 13.0
What does Reoto Takei research?
Reoto Takei's work is mostly in Medicine (76%), Immunology and Microbiology (3%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences5776.0%
- Medicine5776.0%
- Everything else1520.6%
- Life Sciences33.4%
- 1Pulmonary and Respiratory Medicine41% of their works
- 2Epidemiology10% of their works
- 3Pathology and Forensic Medicine10% of their works
- 4Infectious Diseases9% of their works
- 5Physiology6% of their works
- 6Immunology3% of their works
Research topics
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Systemic Sclerosis and Related Diseases
- Inflammatory Myopathies and Dermatomyositis
- Chronic Obstructive Pulmonary Disease (COPD) Research
- COVID-19 Clinical Research Studies
- Sarcoidosis and Beryllium Toxicity Research
- Pulmonary Hypertension Research and Treatments
- SARS-CoV-2 and COVID-19 Research
Which keywords describe Reoto Takei's research?
The keywords of their largest research topics: Fibrosis, Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, TGF-ß, Autoantibodies, Treatment, Endothelial Dysfunction and Diagnosis.
- Coronavirus
- Pulmonary Hypertension
- Cardiac
- Clinical Characteristics
- COPD
- Dermatomyositis
- ACE2 Receptor
- Pulmonary Involvement
- Diagnosis
- Treatment
- TGF-ß
- Interstitial Lung Disease
- Fibrosis
- Idiopathic Pulmonary Fibrosis
- Autoantibodies
- Endothelial Dysfunction
- Management
- Systemic Sclerosis
- SARS-CoV-2
- Inflammatory Myopathies
- spirometry
- Epidemiology
- Sarcoidosis
- Right Heart Assessment
- Vaccine
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 25 words, with their numbers
- Fibrosis682 topics
- Interstitial Lung Disease642 topics
- Idiopathic Pulmonary Fibrosis481 topic
- TGF-ß481 topic
- Autoantibodies362 topics
- Treatment362 topics
- Endothelial Dysfunction282 topics
- Diagnosis252 topics
- Management252 topics
- Pulmonary Involvement201 topic
- Systemic Sclerosis201 topic
- ACE2 Receptor182 topics
- SARS-CoV-2182 topics
- Dermatomyositis161 topic
- Inflammatory Myopathies161 topic
- COPD151 topic
- spirometry151 topic
- Clinical Characteristics111 topic
- Epidemiology111 topic
- Cardiac101 topic
- Sarcoidosis101 topic
- Pulmonary Hypertension81 topic
- Right Heart Assessment81 topic
- Coronavirus71 topic
- Vaccine71 topic
Where does Reoto Takei work?
Reoto Takei's main affiliation in the publication record is Tosei General Hospital, Japan.
How many publications and citations does Reoto Takei have?
OpenAlex counts 75 works and 977 citations for Reoto Takei, an h-index of 17, ranking #832,631 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Reoto Takei. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.